<DOC>
	<DOCNO>NCT00744471</DOCNO>
	<brief_summary>The purpose study test efficacy safety 3 dos tanezumab osteoarthritis hip patient</brief_summary>
	<brief_title>Tanezumab Osteoarthritis Of The Hip</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<criteria>Osteoarthritis hip accord ACR criterion KellgrenLawrence xray grade 2 Unwilling unable take nonopiate pain medication , nonopiate pain medication provide adequate pain relief candidate Hip injection , arthroplasty replacement surgery Pain level function level require protocol Screening Baseline Willing discontinue pain medication ( acetaminophen permit certain level ) study Must agree contraceptive requirement protocol applicable Must agree treatment plan , schedule visit , procedure protocol Pregnancy BMI great 39 Other severe pain , significant cardiac , neurological psychological condition , protocol limit laboratory blood pressure result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>monoclonal antibody RN624 PF-04383119 nerve growth factor anti-nerve growth OA</keyword>
</DOC>